Poloxamer 407 based-nanoparticles for controlled release of methotrexate by Moura, A. et al.
Contents lists available at ScienceDirect
International Journal of Pharmaceutics
journal homepage: www.elsevier.com/locate/ijpharm
Poloxamer 407 based-nanoparticles for controlled release of methotrexate
Soﬁa Moura1, Jennifer Noro1, Patrícia Cerqueira, Carla Silva, Artur Cavaco-Paulo, Ana Loureiro⁎
Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal







A B S T R A C T
Poloxamer 407 (P407)-based nanoparticles were produced by the high pressure homogenization method for the
encapsulation and delivery of methotrexate (MTX), aiming intravenous therapeutic applications. The surface of
these nanoparticles was functionalized by conjugation of P407 with folic acid (FA) or with MTX, which served as
targeting ligand agents. MTX-P407 conjugate was also developed to increase the ﬁnal drug cargo. Two hydro-
phobic derivatives of MTX, MTX di-ethylated ester (MTX-OEt) and the ionic complex MTX-dimethyldioctade-
cylammonium bromide (MTX-DODAB) were produced and entrapped onto P407-based nanoparticles. All for-
mulations developed revealed a monodisperse character comprising small and narrow nanoparticles
(< 100 nm). P407 nanoparticles (functionalized with FA) and MTX-P407 nanoparticles, both loaded with MTX-
OEt, demonstrated a slow drug release proﬁle. The eﬀect of lipase from Aspergillus oryzae on the hydrolysis of the
linkage between the P407 and MTX, and consequent MTX release proﬁle, was also evaluated. We observed a
controlled and slow release of MTX (< 50% of release after 11 days) in the presence of enzyme. These MTX-P407
nanoparticles loaded with MTX-OEt induced a great eﬀect against Caco-2 cancer cells (≈40% of cell death after
72 h of incubation), demonstrating higher eﬃciency than the free MTX at the same concentration.
1. Introduction
Nanomedicine has gained interest as a mean to potentiate the ad-
vantages of eﬃcient drug delivery (Huang et al., 2018), decreasing the
risk of toxicity to the normal tissues and organs of the patient (Alam
et al., 2015). The clever use of nanoparticles has revolutionized how
drugs are formulated and delivered (Rizvi and Saleh, 2018). Nano-
particles have been synthesized using various diﬀerent methods de-
pending of its application and type of drugs to be encapsulated (Pinto
Reis et al., 2006). Loureiro and co-workers, reported a novel method
based on high pressure homogenization of a biphasic system (aqueous
phase and vegetable oil) to produce stable P407-based nanoparticles of
small size (Loureiro et al., 2018). Poloxamers are poly(ethylene oxide)
(PEO)-poly(propylene oxide) (PPO)-poly(ethylene oxide) type of block
copolymers generally expressed as PEOx-PPOy-PEOx (Kabanov et al.,
2002b), where x and y designate the total average number of PEO and
PPO repeat units, respectively (Kedar et al., 2010). This arrangement
results in amphiphilic copolymers (Kabanov et al., 2002a). Reviews that
address Poloxamers have explored speciﬁc structures, such as hydrogels
and Poloxamer-modiﬁed particles (Bodratti and Alexandridis, 2018).
Due to their lateral PEG hydrophilic chains, Poloxamers provide steric
stabilization and prevention of protein adsorption, resulting in less
phagocytized nanoparticles and longer half-life in the systemic circu-
lation (Alexis et al., 2008). Another exceptional feature is that Polox-
amers inhibit eﬄux action of P-glycoprotein (Chen et al., 2013), which
is associated to multidrug resistance (MDR) (Kedar et al., 2010).
MTX is one of the most studied and eﬀective chemotherapeutic
agents available to treat many tumours and autoimmune diseases
(Abolmaali et al., 2014). MTX has also been described as a dual-acting
molecule, due to its high structural similarity to FA, and it can be used
as targeting agent (Loureiro et al., 2016). However, limitations as
toxicity and drug resistance associated to adverse side-eﬀects, poor
aqueous solubility and short circulation half-life of the free acid form of
MTX have been limiting its therapeutic applications (Choi et al., 2018;
Gulfam et al., 2017). To overcome these drawbacks and improve the
drug eﬃcacy and pharmacokinetics many studies have been carried
out. One of the strategies is the development of prodrugs by chemical
modiﬁcation of the MTX. For example, MTX dodecyl ester derivative
was synthetized by esteriﬁcation of the α- and γ-carbonyl groups of the
glutamic acid aiming to increase its lipophilic behaviour, for a higher
encapsulation in a lipid formulation (Moura et al., 2011). Xie and co-
workers synthetized MTX-PEG-DSPE to produce micellar nanoparticles.
This MTX prodrug was used as dual-acting agent, acting simultaneously
as tumour targeting ligand and as anticancer agent, revealing to be an
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interesting example of a drug delivery system (Xie et al., 2018). The
amphiphilic properties of Poloxamer have also been explored on its
conjugation with MTX for the production of polymeric micelles, al-
lowing a sustained release of MTX (Ren et al., 2015).
In this work, P407-based nanoparticles were developed in order to
optimize the encapsulation of MTX and its controlled delivery (Loureiro
et al., 2018). Two hydrophobic MTX derivatives were developed, MTX-
OEt and an ionic complex of MTX-DODAB, and encapsulated on P407-
based nanoparticles. These hydrophobic derivatives revealed higher
encapsulation onto P407-based nanoparticles ability compared to the
commercial MTX. The conjugation of P407 with MTX was also assessed
to produce nanoparticles containing MTX as a dual-acting agent and to
increase the concentration of MTX on the ﬁnal formulation. The bio-
logical eﬀect of these nanoparticles against cancer cells (Caco-2) was
evaluated.
2. Materials and methods
FA, P407, 4-dimethylaminopyridine (DMAP), pyridine, lipase from
Aspergillus oryzae (> 100 000 U/g), dialysis tubes (cut-oﬀ 1 kDa), 2,5-
dihydroxybenzoic acid (DHB) (suitable for matrix assisted laser deso-
rption ionization time-of-ﬂight mass spectroscopy (MALDI-TOF MS)),
NaOH and all culture media and supplements were purchased from
Sigma-Aldrich, USA. N,N′-dicyclohexylcarbodiimide (DCC), DODAB
and MTX were obtained from TCI Chemicals, Belgium. Dialysis mem-
branes (cut-oﬀ 2 kDa), acetonitrile (high performance liquid chroma-
tography (HPLC) grade) and HCl 37% were obtained from Fisher
Scientiﬁc, USA. Anhydrous dimethyl sulfoxide (DMSO) dried under
molecular sieves, was bought from Acros Organics, Belgium. Phosphate
buﬀered saline (PBS) was acquired from Biochrom GmbH, Germany.
Ultrapure water was obtained from a Milli-Q Water Puriﬁcation System,
Germany. Human colonic epithelial cells (Caco-2 cell line) (ATCC, HTB-
37) were obtained from American Type Culture Collection (ATCC), UK.
T75 ﬂasks and 96-well tissue culture polystyrene plates were acquired
from SPL Life Sciences, Korea. CellTiter 96® AQueous Non-Radioactive
Cell Proliferation [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS) assay was
purchased from Promega, USA.
2.1. Synthesis procedures
2.1.1. Synthesis of MTX-P407 and FA-P407 conjugates
The synthesis of FA-P407 and MTX-P407 conjugates was performed
following the procedure previously described by Loureiro et al.
(Loureiro et al., 2018). Brieﬂy, commercial FA or MTX (0.459 g,
1.01 mmol) was dissolved in anhydrous DMSO (20 mL) with DCC
(0.216 g, 1.05 mmol) and DMAP (0.131 g, 1.07 mmol) under nitrogen
atmosphere. After stirring for 2 h at 40 °C and 700 rpm, P407 (1.46 g,
0.10 mmol) was added to the solution. The reaction proceeded over-
night at the same temperature, shielded from the light. Afterwards, the
suspension was ﬁltered by gravity (Prat Dumas, France) followed by
dialysis (cut-oﬀ 2 kDa) for 7 days against PBS. Then, the solution was
centrifuged (6000 rpm for 30 min at 25 °C, using a Beckman Allegra X
155 centrifuge from Beckman Coulter, USA). The supernatant was re-
covered and identiﬁed as the MTX-P407 conjugate. Quantiﬁcation of
MTX and P407 was performed by proton nuclear magnetic resonance
(1H NMR) spectroscopy, as previously described.
2.1.2. Synthesis of MTX-DODAB complex
Commercial MTX was ﬁrstly converted into its carboxylic acid salt
form in order to increase its water solubility. For this, MTX was sus-
pended in water, and 2 eq. of NaOH were added. After complete so-
lubilization of the solid the pH was neutralized. The respective MTX as
sodium salt (MTX-CO2Na) form was recovered after freeze-drying.
Then, MTX-CO2Na (40 mg, 1 eq.) and DODAB (101 mg, 2 eq.) were
dissolved in a mixture of water (4 mL) and ethanol (4 mL). The
suspension was then placed in a water bath at 70 °C and 700 rpm. After
70 min, the yellow solid formed was recovered by ﬁltration and washed
with water. This solid was identiﬁed as the MTX-DODAB complexed
form with two units of DODAB, isolated with η = 45.5% of yield.
NMR (DMSO‑d6) δH: 0.84 (t, J= 5.6 Hz, 12H), 1.24 (m, 128H), 1.61
(m, 9H), 1.73 (m, 3H), 3.13 (s, 3H), 3.19 (s, 12H), 3.67 (s, 1H), 4.74 (s,
2H), 6.57 (s, 2H), 6.82 (d, J = 9.2 Hz, 2H), 7.34 (s, 1H), 7.62 (d,
J = 8.8 Hz, 2H), 7.67 (s, 1H), 8.35 (s, 1H), 8.57 (s, 1H) ppm.
2.1.3. Synthesis of MTX-OEt
The synthesis of MTX as di-ethylated ester form was performed
using the procedure previously reported by us (Cerqueira et al., 2019).
2.2. 1H NMR
Deuterated dimethyl sulfoxide (DMSO‑d6, Cortecnet, France) was
used as NMR solvent and the peak solvent used as internal reference. All
spectra were traced in a 400 MHz Bruker Avance III equipment.
Pyridine (≥99.5%) was used as internal standard for the quantiﬁcation
of MTX. The procedure and methodology were performed as described
(Guimarães et al., 2019). Signal multiplicity is given as: s (singlet), d
(doublet), t (triplet) and m (multiplet).
2.3. MALDI-TOF
MALDI-TOF mass spectra were acquired on a Bruker Autoﬂex Speed
instrument (Bruker Daltonics GmbH) equipped with a 337 nm nitrogen
laser. The procedure was followed as previously described (Loureiro
et al., 2018). DHB was used as matrix and the samples analysed in the
linear negative mode.
2.4. Production of P407-based nanoparticles
The production of the nanoparticles was performed as previously
described by Loureiro et al. (Loureiro et al., 2018). The initial for-
mulations were prepared according to the purpose of the nanoparticles,
where to an aqueous solution of P407 at 5 mg/mL in PBS (pH 7.4) was
added vegetable oil (organic phase) using a 99.5/0.5 ratio (v/v), re-
spectively. For the nanoparticles functionalized with FA at their surface,
the conjugate FA-P407 was added to the aqueous phase of the initial
formulation, as previously reported (Loureiro et al., 2018). Whilst for
the preparation of the MTX-P407 nanoparticles, the aqueous phase was
a solution of this conjugate where the concentration of the P407 was
maintained at 5 mg/mL. For the entrapment of the hydrophobic deri-
vatives of MTX (MTX-DODAB complex and MTX-OEt) in the nano-
particles, these compounds were dissolved in the vegetable oil phase
applied in the initial formulation. These initial formulations were
submitted to homogenization cycles at high pressures (250 and 600 bar,
two stages of pressure) using a high-pressure homogenizer (APV-2000
Homogenizer from SPX, Denmark), which resulted in the nanoparticles
formation. The free drug was separated from the nanoparticles using
PD-10 desalting columns containing Sephadex G-25 Medium (cut-oﬀ
5 kDa) from GE Healthcare, UK. After separation, the free drug was
quantiﬁed by measuring the absorbance at λmax = 303 nm. Prior to
cellular tests, the nanoparticles were ﬁltered under sterile conditions
using 0.22 µm polyethersulfone (PES) ﬁlter (Merck Millipore, Ireland).
2.5. Nanoparticles characterization
2.5.1. Dynamic light scattering (DLS)
The size distribution and surface charge of the produced nano-
particles were analysed by dynamic light scattering using the Malvern
Zetasizer NS from Malvern Instruments, UK. The measurements were
performed using PBS at pH 7.4, at 25 °C (Cerqueira et al., 2019). The
concentration of P407 was kept constant at 1 mg/mL. Nanoparticles
were store for more than 7 months at 4 °C and constant measurements
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of size and PDI over time were performed.
2.5.2. Nanoparticle tracking analysis (NTA)
A quantitative analysis of the nanoparticles was assessed using a
NanoSight NS500 instrument (Salisbury, UK). This system includes a
charge coupled device (CCD) camera that allows visualization and
tracking Brownian motion of laser-illuminated particles in suspension.
The measurements were performed at room temperature and each
video sequence was captured over 60 s. Prior to analysis, the samples
were 10,000 times diluted with water.
2.6. Release proﬁle of MTX
The release of MTX from the nanoparticles was evaluated by dialysis
(cut-oﬀ 1 kDa) against PBS, at two diﬀerent pHs (6.5 and 7.4), in a hot
room kept at 37 °C. Aliquots were taken at diﬀerent time points and the
absorbance was measured in a 96-quartzo microplate at 303 nm using a
Synergy Mx Multi-Mode Reader from BioTek, USA.
The release proﬁle of the MTX from MTX-P407 nanoparticles was
also assessed by the incubating the nanoparticles in a lipase from
Aspergillus oryzae solution. The nanoparticles were transferred to a
dialysis tube (2 mL) and incubated with the lipase (50 μL, activity >
100000 U/g) in the same conditions described above. A control con-
dition was performed without the addition of the lipase.
2.7. Cellular viability assays
2.7.1. Cells and culture conditions
Caco-2 cell line was maintained in a humidiﬁed atmosphere of 5%
CO2 in air at 37 °C, growing in T75 ﬂasks. Caco-2 cells were routinely
grown in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM), supplemented
with 20% (v/v) of Fetal Bovine Serum (FBS), 1% (v/v) of penicillin/
streptomycin solution and 1% (v/v) of Minimum Essential Medium
(MEM) non-essential amino acids.
2.7.2. Cells viability assay
Cell viability was studied using the MTS assay, as previously de-
scribed (Loureiro et al., 2015a). Brieﬂy, Caco-2 cells were seeded in 96-
well tissue culture polystyrene plates at a density of 1 × 104 cells/well
and incubated overnight to promote cell adhesion. The cells were in-
cubated for 48 and 72 h with diﬀerent concentrations of nanoparticles
containing MTX and/or MTX derivatives and respective controls. After
this incubation, an MTS mixture was added and incubated for 4 h at
37 °C, then the absorbance of the formazan product was read at 490 nm.
Each sample was measured in triplicate and two independent experi-
ments were performed, being the results presented as mean value ±
standard deviation (SD). Cell viability was calculated and expressed as
a percentage relative to the negative control (untreated control cells).
2.8. Statistical analysis
Statistical analysis was performed by one-way ANOVA with
GraphPad Prism 5.0 software (La Jolla, CA, USA). Newman-Keuls
Multiple Comparison test was conducted for post hoc comparisons. A P
value < 0.05 was considered to be statistically signiﬁcant.
3. Results and discussion
3.1. Synthesis of MTX-P407 conjugate
The synthesis of MTX-P407 conjugate was performed through an
esteriﬁcation reaction. Similarly to the previous conjugate (FA-P407)
synthetized by us (Loureiro et al., 2018), the reaction was carried using
DCC as coupling agent, with DMAP as base source (Scheme 1).
After removal of all the unreacted MTX and the reactional compo-
nents by dialysis, the expected conjugate was isolated. The
concentration of P407 and MTX in the ﬁnal solution was quantiﬁed by
NMR (Fig. 1). NMR is a powerful tool for quantitative determination of
drugs, providing high speciﬁcity and sensitivity, having great re-
producibility and automation (Guimarães et al., 2019). For this quan-
tiﬁcation, pyridine was added to a certain volume of the conjugate
solution (after freeze-drying) and the concentration of both components
was calculated, as previously described (Guimarães et al., 2019). The
results revealed a MTX concentration of 0.42 ± 0.08 mg/mL, and a
P407 concentration of 29.85 ± 0.21 mg/mL. Moreover, based on the
integration of the peaks corresponding to MTX and to P407 it was
possible to infer 44.7% of modiﬁcation of P407 with MTX. This meth-
odology allowed, by using a single analysis, to quantify both compo-
nents with high levels of reproducibility. Despite being possible to
quantify MTX by absorbance analysis, no reports were found about the
P407 quantiﬁcation using this methodology. Thus, this technique did
not seemed the ideal for the simultaneous quantiﬁcation of both com-
ponents on the conjugate.
In the 1H NMR spectrum of MTX-P407 conjugate (Fig. 1) is possible
to observe the typical signals of MTX and P407. The patterns of all
signals remained the same as in the starting materials spectra. Protons
near the glutamic moiety, appear at diﬀerent chemical shifts, as already
observed for FA-P407 conjugate (Loureiro et al., 2018).
The molecular weight of the conjugate was also assessed by MALDI-
TOF mass spectrometry (Fig. S1, Supporting information). The MALDI-
TOF spectra of the MTX-P407 conjugate showed a m/z of
13372.242 Da, revealing that only one molecule of MTX was con-
jugated with each molecule of P407 (MWaverage of MTX-P407 conjugate
– MWaverage of P407 = 194.467 Da). The mass diﬀerence detected was
lower than the MWaverage of MTX obtained by MALDI-TOF analysis
(431.783 Da – data not shown). Considering that the spectra was ac-
quired in negative linear mode, only average masses were detected,
which might explain the diﬀerences obtained between the monomer
and the conjugate (Loureiro et al., 2018).
The level of P407 modiﬁcation inferred by MALDI-TOF analysis
(45.0%) was similar to the one obtained by 1H NMR (44.7%).
3.2. Synthesis of hydrophobic MTX derivatives
The commercial MTX presents very low solubility either in organic
or aqueous solvents. Two hydrophobic MTX derivatives (MTX-DODAB
complex and MTX-OEt) were produced (Scheme 2), aiming to improve
its lipophilic character and increase its concentration on the organic
phase (vegetable oil) of the P407-based nanoparticles.
The ionic complex between MTX and DODAB was synthetized as
described in section 2.1.2. We found the addition of two equivalents of
DODAB crucial for the complex formation, resulting in two units of the
quaternary amine complexed with both carboxylic groups of MTX. The
number of DODAB units was determined by 1H NMR (Fig. 2) and ESI
(m/z = 1552 – data not shown). The ionic complex was isolated after
precipitation in water (η = 45%). The 1H NMR spectra of the ionic
complex showed all the typical peaks of MTX and DODAB. The MTX
peaks reveal the same pattern as previously reported (Cerqueira et al.,
2019), with small chemical shifts, especially of the protons g, h and j/i,
which are close to the complexed carboxylic groups.
MTX-OEt was produced as described by Cerqueira et al. (Cerqueira
et al., 2019) (Scheme 2) and its encapsulation in P407-based nano-
particles was tested without any further modiﬁcation. We tested the
encapsulation of this prodrug due to this hydrophobic nature but also
due to its promising biological eﬀect against cancer cells (Caco-2 cell
line), previously described by Cerqueira et al. (Cerqueira et al., 2019).
3.3. Production and characterization of the P407-based nanoparticles
P407 features several advantages like biocompatibility and high
solubility in aqueous solvents and for these reasons has been ex-
tensively applied on the production of nanodevices for diverse
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Scheme 1. Reactional scheme for the synthesis of MTX-P407 conjugate.
Fig. 1. 1H NMR spectrum of MTX-P407 conjugate in DMSO‑d6. The peaks labelled in lowercase blue letters correspond to the protons indicated in the structures of
MTX (letters from a to j) and P407 (letters k and l). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Scheme 2. Reactional schemes for the synthesis of MTX-DODAB ionic complex and MTX-OEt.
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applications (Breitenbach et al., 2017). Loureiro et al. described the use
of the high pressure homogenization method to produce P407-based
nanoparticles with suitable properties for therapeutic applications
(Loureiro et al., 2018). These nanoparticles showed potentiality for
intravenous (IV) administration (small and stealth nanoparticles) and
demonstrated the ability to be eﬃciently internalized by cancer cells.
Nanoparticles larger than 100 nm can be easily cleared-oﬀ by
macrophages and other mononuclear phagocyte system (MPS) cells and
cleared from circulation by phagocytosis (Zahr et al., 2006). Ad-
ditionally, nanoparticles below 10 nm have a higher tendency to be
excreted by the kidneys (Danaei et al., 2018). Therefore, the range
between 10 nm and 100 nm is considered the most appropriate for IV
administration to reach the target cells (Loureiro et al., 2015b). Popu-
lations presenting polydispersity values (PDI) ≤ 0.2 are considered
acceptable for polymer-based nanoparticles (Danaei et al., 2018), re-
presenting monodisperse populations of nanoparticles (Cun et al., 2010;
Hornig et al., 2009) with the ideal physicochemical conditions for IV
administration.
In this work, empty P407 based-nanoparticles functionalized or
nonfunctionalized with FA were produced and their performance was
compared with the nanoparticles produced using the MTX-P407 con-
jugate. The physicochemical characterization of the nanoparticles per-
formed by DLS and NTA techniques (Table 1) indicate that these na-
noparticles present suitable characteristics for IV administration. All
formulations revealed similar small size (91–98 nm) and monodisperse
populations (PDI < 0.2), indicating that the MTX-P407 conjugate did
not inﬂuence negatively the nanoparticles formation, leading, on the
other hand, to the formation of higher concentration of particles
(Table 1, NTA results).
3.4. Encapsulation of MTX-derivatives in P407-based nanoparticles
The hydrophobic derivatives of MTX (MTX-DODAB and MTX-OEt),
as well as the unmodiﬁed MTX, were encapsulated in the produced
nanoparticles (Table 2). Due to its poor solubility in organic or aqueous
media, the lowest ﬁnal drug concentration was obtained when en-
capsulating unmodiﬁed MTX. As expected, the highest amount of MTX/
MTX derivative on the ﬁnal formulation was achieved for the MTX-
P407 nanoparticles loaded with MTX-OEt. The amount of MTX on the
loaded formulations derives from MTX linked to P407 at the nano-
particles’ shell, and from MTX-OEt entrapped onto the nanoparticles.
For this reason, the molar concentration of MTX/MTX derivative was
not inferred since the formulation is composed by two diﬀerent types of
MTX which cannot be distinguished using the indirect absorbance
quantiﬁcation method applied herein.
From Table 2 one can also highlight that all the loaded nano-
particles reveal sizes similar to the empty nanoparticles (Table 1) cor-
responding to monodisperse populations (< 0.150). All formulations
have neutral surface charge (zeta-potential values around 0 ± 2 mV).
The neutral and hydrophilic surface, conferred by the presence of PEG
chains of the P407, can lead to a longer half-life in the blood circulation
(Zahr et al., 2006), which in turns the developed formulations suitable
for IV therapeutic applications. The formulations revealed also high
stability along time, demonstrated by the maintenance of their physi-
cochemical properties even after 7 months of storage (data not shown).
Considering the highest concentration of drug at the ﬁnal for-
mulations, the P407 nanoparticles encapsulating MTX-OEt (functiona-
lized with FA for a speciﬁc delivery) or the MTX-P407 nanoparticles
encapsulating MTX-OEt were chosen for posterior assays.
Fig. 2. 1H NMR spectrum of MTX-DODAB ionic complex in DMSO‑d6. The peaks labelled in lowercase blue letters correspond to the protons indicated in the
structures of MTX (letters from a to j) and DODAB (letters from k to n). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
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3.5. Release proﬁle of MTX from P407-based nanoparticles
The in vitro release of MTX from the P407-based nanoparticles
loaded with MTX-OEt was evaluated at 37 °C through dialysis of the
MTX from the bulk formulations and after incubation of the MTX-P407
nanoparticles with a lipase (Fig. 3). The release of MTX was performed
at two diﬀerent pHs, at physiological pH (7.4, full line) and at acidic
pH, mimicking the tumor microenvironment (6.5, dash line) (Cao et al.,
2017; Lei et al., 2016; Zhang et al., 2016).
Many nanodevices have been studied for the encapsulation and
release of MTX, however most of the strategies revealed the release of
all the drug content after 48 h (Karasulu et al., 2007; Nogueira et al.,
2016; Zhao et al., 2016).
The P407-based nanoparticles tested, as functionalized with FA or
prepared with MTX-P407 conjugate, revealed a similar slow release
proﬁle, at both pH tested, as depicted in Fig. 3. As P407 is a non-ionic
polymer it would be expected that small diﬀerences in the buﬀer pH
would not aﬀect the stability of the nanoparticles, and therefore their
release proﬁle.
FA-tagged P407 nanoparticles showed the highest MTX release at
both pH tested (> 50% after 272 h, Fig. 3, red lines) than the nano-
particles prepared using the MTX-P407 conjugate (≈30% after 272 h,
Fig. 3, black lines). The data is presented in terms of MTX percentage
release relatively to the total amount in the ﬁnal formulations. Con-
sidering that MTX-P407 nanoparticles are composed by a higher
amount MTX/MTX derivative (entrapped MTX-OEt and MTX con-
jugated to P407), when comparing with the FA-tagged P407 nano-
particles, a lower percentage of release after 272 h is observed. We
might speculate that the MTX-OEt present in the hydrophobic core of
both formulations is more easily released from the nanoparticles than
the MTX covalently linked to P407, which would be more hardly dis-
rupted. In this way, the FA-tagged nanoparticles release a higher per-
centage of MTX, than the formulations composed by the MTX-P407
conjugate.
In a biological environment, the nanoparticles are susceptible to
degradation by a panoply of hydrolytic enzymes (Rios-Ramírez, 2013),
being esterases an example of enzymes involved in drug metabolism
(Fukami and Yokoi, 2012). In this way, the role of lipase from Asper-
gillus oryzae on the MTX-P407 conjugate hydrolysis was undertaken
(Fig. 3, blue lines). We chose this lipase based on its aﬃnity for large
substrates, such as acylglycerols (Toida et al., 1995). During all the
dialysis processing, the enzyme remained stable (no signiﬁcant activity
loss until 1 month at 37 °C). At pH 7.4, MTX-P407 nanoparticles loaded
with MTX-OEt, even after incubation with lipase, revealed a lower MTX
release (≈ 38% after 272 h) than observed for the FA-tagged P407
nanoparticles. At pH 6.5, the enzyme action was responsible for an
Table 1
Physicochemical characterization of P407-based nanoparticles functionalized and nonfunctionalized with FA and of MTX-P407 nanoparticles, measured by DLS and
NTA. Values represent the mean ± SD of two independent experiments.
DLS NTA
Z-average (nm) Polydispersity index (PDI) Mean (nm) SD (nm) Conc, particles (particles/mL)
P407 nanoparticles 98.4 ± 2.9 0.176 ± 0.041 98.0 ± 10.1 43.5 ± 16.8 2.8 ± 0.38 (E12)
FA-tagged P407 nanoparticles 92.3 ± 3.7 0.118 ± 0.001 98.8 ± 8.4 43.5 ± 15.1 2.7 ± 0.23 (E12)
MTX-P407 nanoparticles 91.3 ± 24.4 0.122 ± 0.003 97.0 ± 5.7 39.0 ± 3.9 5.1 ± 0.61 (E12)
Table 2
Physicochemical characterization of the nanoparticles (evaluated by DLS) and ﬁnal drug concentration in the formulations. Values represent the mean ± SD of two
independent experiments.
P407-based nanoparticles MTX encapsulated Z-average (d·nm) PDI [MTX/MTX derivatives] at the ﬁnal formulations*
mg/mL mM**
P407 Unmodiﬁed MTX 97.3 ± 10.8 0.105 ± 0.020 0.009 ± 0.004 0.020 ± 0.008
P407 MTX-DODAB 94.7 ± 4.1 0.094 ± 0.013 0.066 ± 0.001 0.042 ± 0.000
FA-tagged P407 MTX-DODAB 95.1 ± 7.9 0.099 ± 0.008 0.067 ± 0.001 0.043 ± 0.000
P407 MTX-OEt 86.7 ± 6.7 0.096 ± 0.013 0.041 ± 0.018 0.078 ± 0.040
FA- tagged P407 MTX-OEt 86.1 ± 1.7 0.096 ± 0.023 0.032 ± 0.006 0.059 ± 0.017
MTX-P407 – 91.3 ± 24.4 0.122 ± 0.003 0.031 ± 0.005 0.067 ± 0.011
MTX-P407 MTX-OEt 84.0 ± 12.7 0.132 ± 0.003 0.046 ± 0.003 –***
* Concentration of drug in the nanoparticles after dilution of 1.4x in the PD-10 desalting columns.
** The molar concentration was also calculated because the MTX-DODAB complex presents a very high molecular weight (1554.52 g/mol) comparatively to the
MTX (454.44 g/mol) and the MTX-OEt (510.55 g/mol), resulting in a great diﬀerence on the molar concentration.
*** Not possible to determine.
Fig. 3. Release over time of MTX from the P407 nanoparticles functionalized
with FA and MTX-P407 nanoparticles, both loaded with MTX-OEt (red and
black lines, respectively), and release of MTX from the MTX-P407 nanoparticles
in the presence of lipase from Aspergillus oryzae (blue lines). Physiological pH
(7.4, full line) and acidic pH (6.5, dash line). The values are a mean of two
independent experiments. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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increase of the MTX release from the MTX-P407 nanoparticles loaded
with MTX-OEt to the levels obtained for the FA-tagged P407 nano-
particles (≈50% after 272 h of incubation).
The presence of lipase incremented only 10% (pH = 7.4) and 15%
(pH = 6.5) of MTX release from MTX-P407 nanoparticles. Considering
the low release increment promoted by lipase, which in theory would
break the linkage between P407 and MTX, one might speculate that the
MTX-P407 formulations are composed mainly by MTX-OEt. This MTX
derivative, at the time of particles formation, is dissolved in vegetable
oil being entrapped onto the hydrophobic core, which in turns its re-
lease slow, as in absence or in presence of enzyme.
Both nanoparticles (FA-tagged P407 and MTX-P407 nanoparticles)
revealed a controlled and sustained drug release demonstrating po-
tentiality to serve as release matrixes, reducing the dose frequency and
increasing the patient compliance.
3.6. Biological eﬀect of P407-based nanoparticles loaded with MTX-OEt
Previous studies revealed that P407-based nanoparticles (up to
900 µg/mL) did not induce cytotoxicity in immortalized human normal
cells, even after 72 h of incubation (Loureiro et al., 2018). For this
reason, we can consider that these nanoparticles are not harmful to
normal cells, being promising candidates for therapeutic applications.
In order to evaluate the biological eﬀect of the P407-based nano-
particles loaded with MTX-OEt (functionalized or not with FA), the cell
viability of cancer cells was assessed. Caco-2 cell line was chosen for the
biological evaluation since it endogenously express folate receptor (FR)
(Doucette and Stevens, 2001).
The results demonstrated that, as expected, empty nanoparticles
(with or without FA) did not induce a signiﬁcant loss of cell viability
(Fig. 4). The free prodrug (MTX-OEt) or loaded into the nanoparticles
displayed very similar eﬀect on the cell viability (≈70%), conﬁrming
the ability of nanoparticles to release the MTX derivative when inter-
nalized by the cells. The FA-tagged nanoparticles loaded with 5 µg/mL
of MTX-OEt showed a more pronounced biological eﬀect against cancer
cells, comparing with the eﬀect of the same concentration of free MTX-
OEt (but not statistically signiﬁcant). We might deduce that these FA-
tagged nanoparticles were recognized by the FR at the surface of Caco-2
cells being internalized by FR-mediated endocytosis, releasing further
the drug as intended.
The biological eﬀect of the P407-based nanoparticles loaded with
MTX-OEt was not signiﬁcant due to the low concentration of drug ap-
plied. In order to increase the total concentration of drug applied (to
8 µg/mL) in Caco-2 cells, the biological eﬀect of the MTX-P407 nano-
particles was also evaluated. Fig. 5 shows the Caco-2 cell viability after
48 and 72 h of incubation with: empty MTX-P407 nanoparticles, MTX-
P407 nanoparticles loaded with MTX-OEt and respective controls.
The results revealed that all the tested nanoparticles and the MTX-
P407 conjugate did not induce a signiﬁcant loss of cell viability after
48 h of incubation. However, after 72 h of incubation, the MTX-P407
nanoparticles loaded with MTX-OEt induced approximately 40% of cell
death, indicating disruption or release of MTX/MTX derivative from the
nanoparticles. The biological eﬀect observed only after 72 h of in-
cubation, can be explained by the slow release proﬁle of MTX during
the dialysis studies. The free MTX and MTX-OEt demonstrated lower
cytotoxicity than when entrapped onto the nanoparticles, conﬁrming
the role of the nanodevices on the internalization and release of the
drug inside the cells. The cells incubated with the MTX-P407 conjugate
showed 100% of cell viability even after 72 h of incubation. One might
claim that the produced conjugate, in the free form, is not internalized
by the cells and consequently is not subjected to the action the cell
machinery. Since no internalization and disruption occurred, this con-
jugate did not induce biological eﬀect on cancer cells.
The slow MTX release proﬁle observed previously, together with the
great biological eﬀect against cancer cells, revealed MTX-P407 nano-
particles loaded with the hydrophobic MTX derivative (MTX-OEt) as a
new outstanding methodology for cancer therapy.
Fig. 4. Caco-2 cell viability after 48 h of contact with P407-based nanoparticles
(functionalized or nonfunctionalized with FA) containing or not 5 µg/mL of
MTX-OEt and with the MTX derivative alone at the same concentration, com-
pared with cells (negative control) and cells incubated with 30% (v/v) of DMSO
(death control), determined by MTS assay. Values are the mean ± SD of two
independent experiments. Statistical signiﬁcant diﬀerences from the negative
control are indicated as: * P-value < 0.05 and *** P-value < 0.0001. Values
of FA-P407 nanoparticles + MTX-OEt and MTX-OEt alone are not statistically
signiﬁcant.
Fig. 5. Caco-2 cell viability after 48 and 72 h of contact with: empty MTX-P407
nanoparticles; MTX-P407 nanoparticles loaded with MTX-OEt; MTX-P407
conjugate; and the two types of MTX (unmodiﬁed MTX and MTX-OEt), at the
same concentration (8 µg/mL), compared with cells (negative control) and cells
incubated with 30% (v/v) of DMSO (death control), determined by MTS assay.
Values are the mean ± SD of two independent experiments. Statistical sig-
niﬁcant diﬀerences from the negative control are indicated as: *P-value <
0.05; **P-value < 0.01 and ***P-value < 0.0001.
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4. Conclusions
P407-based nanoparticles loaded with diﬀerent MTX derivatives
were successfully produced. These nanoparticles remained stable for
more than 7 months of storage, maintaining their physicochemical
proprieties suitable for IV therapeutic applications. The encapsulation
of two hydrophobic MTX derivatives (MTX-OEt and MTX-DODAB) into
the hydrophobic core of the nanoparticles revealed MTX-OEt as the best
prodrug to increase the ﬁnal drug cargo on the developed formulations.
The P407-based nanoparticles loaded with MTX-OEt revealed a slow
drug release proﬁle, which confers a great advantage relatively to many
nanodevices recently studied for the encapsulation and release of MTX.
MTX-P407 nanoparticles loaded with MTX-OEt showed a great biolo-
gical eﬀect against cancer cells, demonstrating to be more eﬀective than
the same concentration of free MTX. All these ﬁndings allow us to en-
visage the IV therapeutic application of these nanoparticles in order to
potentiate the MTX therapeutic eﬀect and overcome its several limita-
tions. Thus, the developed nanoparticles demonstrated several po-
tentialities to be implemented as a drug delivery system in cancer
therapy.
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